Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief Executive...

Fri Oct 10, 2008 9:00am EDT

* Reuters is not responsible for the content in this press release.

Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief
Executive Officer and Jeffrey Jenson, Head of Clinical Operations.

CARLSBAD, Calif., Oct. 10 /PRNewswire/ -- Excaliard Pharmaceuticals, a late
stage preclinical company developing targeted therapeutics for the treatment
of dermatological disorders and fibrotic diseases, is pleased to announce the
appointment of Lincoln Krochmal, MD, as President & Chief Executive Officer
and Jeff Jensen as Head of Clinical Operations.

Dr. Lincoln Krochmal is a board certified Dermatologist with over 25 years
experience in the pharmaceutical and consumer goods industries. Prior to
joining Excaliard in September of 2008, Dr. Krochmal served as Executive Vice
President, Research and Product Development for Connetics Corporation, a
specialty dermatology company headquartered in Palo Alto, CA, until the
company's acquisition by Stiefel Laboratories, Inc.  Dr. Krochmal began his
industrial career with Westwood Pharmaceuticals (the dermatology subsidiary of
Bristol-Myers Squibb) becoming VP, Dermatology Research & Development and VP,
Worldwide Medical Development. He then joined Unilever PLC, where he spent the
next decade in various executive management positions including SVP, Home and
Personal Care Research & Development directing the worldwide development of
numerous consumer products including helping to build the Dove(R) brand to a $
2 billion dollar global business.

During his career, Dr. Krochmal has played a pivotal role in the approval of
15 NDAs/ANDAs for new topical dermatologicals including LacHydrin(R),
Ultravate(R), Dovonex(R), Evoclin(R), Verdeso(R), Olux-E(R) and Extina(R) and
numerous OTC and consumer goods in the US and internationally.

Dr. Krochmal received his Doctor of Medicine from the Medical College of
Wisconsin, and is board certified in dermatology. Dr. Krochmal serves on the
board of directors for the International Academy of Cosmetic Dermatology and
Quinnova Pharmaceuticals, Inc. He is a fellow of the American Academy of
Dermatology, a Diplomat of the American Board of Dermatology, a member of the
International Society of Dermatology and the Dermatology Foundation.

Jeff Jensen brings to Excaliard over 25 years of clinical operations
experience and has successfully overseen the outsourcing of hundreds of
clinical trials. Prior to joining Excaliard, he was Senior Director of
Clinical Operations at Metabasis Therapeutics and a Director of Study
Management and Development Operations at Pfizer. In addition, Mr. Jensen has
held senior level positions at some of the industry's top clinical research
organizations. He was Vice-President of Operations at INC Research, a leading
CNS and oncology CRO, Chief Operating Officer for Therapeutic Management, and
Director of Clinical Operations at Quintiles. Before joining INC Research he
gained international experience as Director of Clinical Research in Europe at
Pharmaco LSR (currently PPD). Mr. Jensen earned a Bachelor of Science degree
in Biochemistry and Biophysics at Oregon State University.

"Having helped the company get started over the last year it was now time to
bring on a fulltime CEO, as well as strengthen clinical operations," said Dr.
Gordon Foulkes, Excaliard's acting CEO and a Managing Director at RiverVest
Venture Partners. "The Board could not be more enthusiastic than with the
appointment of Dr Krochmal to lead the company going forward. His track record
in drug approvals in this area is truly outstanding . We are also extremely
pleased to have Jeff Jensen join Excaliard as Head of Clinical Operations as
he brings a wealth of invaluable experience in clinical trials operations."

"I am delighted to be joining the dynamic and outstanding team at Excaliard
Pharmaceuticals at a critically important time in the development of their
proprietary technology as we move into clinical studies," said Dr. Lincoln
Krochmal. "This technology has the potential to offer patients real benefit
for a truly unmet medical need which is very exciting."


SOURCE  Excaliard Pharmaceuticals

Lincoln Krochmal, M.D., President and Chief Executive Officer of Excaliard
Pharmaceuticals, +1-760-431-1850
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.